ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL.7, 2012, Pages 19-37

  Cornely, O A ^a   Bassetti, M ^b   Calandra, T ^c   Garbino, J ^d   Kullberg, B J ^e   Lortholary, O ^f,g   Meersseman, W ^h   Akova, M ⁱ   Arendrup, M C ^j   Arikan Akdagli, S ⁱ   Bille, J ^c   Castagnola, E ^k   Cuenca Estrella, M ^l   Donnelly, J P ^e   Groll, A H ^m   Herbrecht, R ⁿ   Hope, W W ^o   Jensen, H E ^p   Lass Florl C ^q   Petrikkos, G ^r   Richardson, M D ^s   Roilides, E ^t   Verweij, P E ^e   Viscoli, C ^u   Ullmann, A J ^v   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b S Maria Hospital   (Italy)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g INSTITUT PASTEUR   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HACETTEPE UNIVERSITY   (Turkey)

^j STATENS SERUM INSTITUT   (Denmark)

^k G GASLINI INSTITUTE   (Italy)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITÉ DE STRASBOURG   (France)

^o UNIVERSITY OF LIVERPOOL   (United Kingdom)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

^q INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^r UNIVERSITY OF ATHENS   (Greece)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^u UNIVERSITY OF GENOA   (Italy)

^v UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Candidiasis; Guideline; Non neutropenic; Prophylaxis; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; EFUNGUMAB; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NEOMYCIN; NYSTATIN; PLACEBO; POLYMYXIN B; POSACONAZOLE; RIFAMPICIN; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ANASTOMOSIS LEAKAGE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ARTIFICIAL HEART PACEMAKER; ASPERGILLOSIS; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA ENDOCARDITIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA MENINGITIS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CHILL; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; CYSTITIS; DIGESTIVE SYSTEM PERFORATION; DISEASE DURATION; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; ENDOPHTHALMITIS; EYE INFECTION; FEVER; FUNGEMIA; FUNGUS ISOLATION; HEART VALVE PROSTHESIS; HEART VALVE SURGERY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INDWELLING CATHETER; INTERVERTEBRAL DISK DEGENERATION; INVASIVE CANDIDIASIS; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OCULAR CANDIDIASIS; OPHTHALMOSCOPY; OSTEOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; PYELONEPHRITIS; RECURRENT DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTRICULAR ASSIST DEVICE; ADULT; CANDIDA; DRUG EFFECT; EVIDENCE BASED MEDICINE; ISOLATION AND PURIFICATION;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84867709158     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12039     Document Type: Article

References (173)

1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39: 665-670.
2. Azoulay E, Dupont H, Tabah A et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012; 40(3): 813-822.
3. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
4. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49: 3300-3308.
5. Ostrosky-Zeichner L, Shoham S, Vazquez J et al. Msg-01: a multicenter, randomized, double-blind, placebo controlled trial of caspofungin (cas) prophylaxis vs placebo followed by pre-emptive therapy for invasive candidiasis (ic) in high-risk adults in the critical care setting. Preliminary results. SHEA Annual Scientific Meeting. Dallas, Texas, United States, 2011.
6. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
7. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.
8. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072.
9. Senn L, Eggimann P, Ksontini R et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 2009; 35: 903-908.
10. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548.
11. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717.
12. de Smet AM, Kluytmans JA, Cooper BS et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360: 20-31.
13. de Smet AM, Kluytmans JA, Blok HE et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011; 11: 372-380.
14. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005; 31: 1479-1487.
15. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-1935; quiz 1936.
16. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57: 628-638.
17. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006; 1: CD004920.
18. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34: 1216-1224.
19. de Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (eortc/msg) consensus group. Clin Infect Dis 2008; 46: 1813-1821.
20. Cerra FB, Maddaus MA, Dunn DL et al. Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg 1992; 127: 163-167; discussion 167-169.
21. Havlicek K, Cervinka V, Sakra L, Motycka V, Mencl K. Preemptive antimycotic treatment in critically ill patients in the Czech Republic. Int Surg 2008; 93: 244-246.
22. Slotman GJ, Burchard KW. Ketoconazole prevents candida sepsis in critically ill surgical patients. Arch Surg 1987; 122: 147-151.
23. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
24. Mann PA, McNicholas PM, Chau AS et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of candida species. Antimicrob Agents Chemother 2009; 53: 5026-5034.
25. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-albicans candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-1213.
26. Holzknecht BJ, Thorup J, Arendrup MC et al. Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis*. Clin Microbiol Infect 2011; 17: 1372-1380.
27. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-190.
28. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
29. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive candida species infections. J Antimicrob Chemother 2007; 60: 613-618.
30. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
31. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10: 882-885.
32. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-5962.
33. Takesue Y, Kakehashi M, Ohge H et al. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004; 28: 625-630.
34. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1, 3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009; 13: 707-712.
35. Mohr JF, Sims C, Paetznick V et al. Prospective survey of (1-->3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49: 58-61.
36. Posteraro B, De Pascale G, Tumbarello M et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-->3)-beta-d-glucan assay, candida score, and colonization index. Crit Care 2011; 15: R249.
37. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-1659.
38. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
39. Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 3871-3874.
40. Kontoyiannis DP, Reddy BT, Torres HA et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34: 400-403.
41. Franquet T, Muller NL, Lee KS, Oikonomou A, Flint JD. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section ct findings. Radiology 2005; 236: 332-337.
42. Meersseman W, Lagrou K, Spriet I et al. Significance of the isolation of candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35: 1526-1531.
43. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin b followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
44. Lecciones JA, Lee JW, Navarro EE et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-883.
45. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
46. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
47. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
48. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and mds: comparison of the data from the annual of the pathological autopsy cases in japan in 1989, 1993 and 1997. Pathol Int 2003; 53: 744-750.
49. Edwards JE Jr, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections [see comments]. Clin Infect Dis 1997; 25: 43-59.
50. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin b formulations in immunocompromised patients in 4 european countries. Clin Infect Dis 2006; 43: e29-e38.
51. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin b therapy. Clin Infect Dis 2001; 32: 686-693.
52. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin b and review of the literature. Clin Infect Dis 1996; 23: 964-972.
53. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin b for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute. N Engl J Med 1994; 331: 1325-1330.
54. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin b for treatment of candidemia in non-neutropenic patients. Canadian candidemia study group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-345.
55. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin b for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
56. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin b deoxycholate infused over 4 or 24hours: randomised controlled trial. BMJ (Clinical Research ed.) 2001; 322: 579-582.
57. Anaissie E, White MH, Uzun O et al. Amphotericin b lipid complex versus amphotericin b for treatment of invasive candidiasis: a prospective, randomized multicenter trial. 35th Interscience Conference on Antimivrobial Agents and Chemotherapy. San Francisco, 1995.
58. Ito JI, Hooshmand-Rad R. Treatment of candida infections with amphotericin b lipid complex. Clin Infect Dis 2005; 40 (suppl 6): S384-S391.
59. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin b versus amphotericin b lipid complex in the empirical treatment of febrile neutropenia. L amph/ablc collaborative study group. Clin Infect Dis 2000; 31: 1155-1163.
60. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin b colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461-467.
61. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin b for candidaemia and invasive candidosis: a phase iii randomised double-blind trial. Lancet 2007; 369: 1519-1527.
62. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin b. Crit Care 2009; 13: R159.
63. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893.
64. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
65. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 idsa treatment guidelines for candidiasis. Crit Care 2011; 15: R253.
66. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata: results from the sentry antimicrobial surveillance program (2006-2010) and the centers for disease control and prevention population-based surveillance (2008-2010). J Clin Microbiol 2012; 50(4): 1199-1203.
67. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
68. Anonymous. Mycamine: European public assessment report (epar) product information. Edited by Agency EM. European Medicines Agency, London, UK, 2011.
69. Anonymous. Ecalta: European public assessment report (epar) product information. Edited by Agency EM. European Medicines Agency, London, UK, 2011.
70. Anonymous. Cancidas: European public assessment report (epar) product information. Edited by Agency EM. European Medicines Agency, London, UK, 2011.
71. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009; 48: 503-535.
72. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1011-1021.
73. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive candida infections in critical care: a multicenter, prospective, observational study in france (2005-2006). Crit Care Med 2009; 37: 1612-1618.
74. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin b as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228.
75. Abele-Horn M, Kopp A, Sternberg U et al. A randomized study comparing fluconazole with amphotericin b/5-flucytosine for the treatment of systemic candida infections in intensive care patients. Infection 1996; 24: 426-432.
76. Tuil O, Cohen Y. Itraconazole iv solution in the treatment of candidemia in non-neutropenic patients. Crit Care 2003; 7: 63-64.
77. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
78. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 651-655.
79. Anonymous. Vfend: European public assessment report (epar) product information. Edited by Agency EM. European Medicines Agency: London, UK, 2011.
80. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
81. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006; 43: 1083; author reply 1083-1084.
82. Oude Lashof AM, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003; 22: 43-48.
83. Fernández-Cruz A, Menárguez MC, Pedromingo M et al. Candida endocarditis: yield of echocardiogram in patients with candidemia. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, 2010; K-2172.
84. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine 2003; 82: 187-202.
85. Brooks RG. Prospective study of candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989; 149: 2226-2228.
86. Parke DW II, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology 1982; 89: 789-796.
87. Oude Lashof AM, Rothova A, Sobel JD et al. Ocular manifestations of candidemia. Clin Infect Dis 2011; 53: 262-268.
88. Davey ME, O'Toole GA. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 2000; 64: 847-867.
89. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of candida biofilms: unique efficacy of amphotericin b lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-1780.
90. Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob Agents Chemother 2010; 54: 4474-4475.
91. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin b lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated candida biofilms. Int J Antimicrob Agents 2009; 33: 149-153.
92. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. Niaid mycoses study group and the candidemia study group. Clin Infect Dis 1995; 21: 994-996.
93. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
94. Weinberger M, Leibovici L, Perez S et al. Characteristics of candidaemia with Candida-albicans compared with non-albicans candida species and predictors of mortality. J Hosp Infect 2005; 61: 146-154.
95. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of candida bloodstream infection: results from population-based surveillance, barcelona, spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
96. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-793.
97. Liu CY, Huang LJ, Wang WS et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 2009; 58: 154-160.
98. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 1110-1122.
99. Revankar SG, Hasan MS, Revankar VS, Sobel JD. Long-term follow-up of patients with candiduria. Eur J Clin Microbiol Infect Dis 2011; 30: 137-140.
100. Kauffman CA, Vazquez JA, Sobel JD et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The national institute for allergy and infectious diseases (niaid) mycoses study group. Clin Infect Dis 2000; 30: 14-18.
101. Sobel JD, Kauffman CA, McKinsey D et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The national institute of allergy and infectious diseases (niaid) mycoses study group. Clin Infect Dis 2000; 30: 19-24.
102. Tuon FF, Amato VS, Penteado Filho SR. Bladder irrigation with amphotericin b and fungal urinary tract infection-systematic review with meta-analysis. Int J Infect Dis 2009; 13: 701-706.
103. Malani AN, Kauffman CA. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 2007; 5: 277-284.
104. Bartone FF, Hurwitz RS, Rojas EL, Steinberg E, Franceschini R. The role of percutaneous nephrostomy in the management of obstructing candidiasis of the urinary tract in infants. J Urol 1988; 140: 338-341.
105. Shih MC, Leung DA, Roth JA, Hagspiel KD. Percutaneous extraction of bilateral renal mycetomas in premature infant using mechanical thrombectomy device. Urology 2005; 65: 1226.
106. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007; 44: e46-e49.
107. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of candida septicemia: review of seventy-six cases of hematogenous candida endophthalmitis. Medicine 1974; 53: 47-75.
108. Chhablani J. Fungal endophthalmitis. Expert Rev Anti Infect Ther 2011; 9: 1191-1201.
109. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992; 14: 472-478.
110. Essman TF, Flynn HW Jr, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 185-194.
111. Virata SR, Kylstra JA, Brown JC, Wohl DA, Cohen MS. Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin b. Clin Infect Dis 1999; 28: 1177-1178.
112. Darling K, Singh J, Wilks D. Successful treatment of Candida glabrata endophthalmitis with amphotericin b lipid complex (ablc). J Infect 2000; 40: 92-94.
113. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin b in a rabbit model. Antimicrob Agents Chemother 2002; 46: 3719-3723.
114. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Corneal concentrations following systemic administration of amphotericin b and its lipid preparations in a rabbit model. Ophthalmic Res 2004; 36: 172-176.
115. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin b. Am J Ophthalmol 1973; 76: 578-583.
116. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: e27-e28.
117. Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (fk463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322-3327.
118. Groll AH, Mickiene D, Petraitiene R et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (ly303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45: 2845-2855.
119. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-2524.
120. Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-369.
121. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40: e46-e48.
122. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995; 119: 477-481.
123. Laatikainen L, Tuominen M, von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 1992; 113: 205-207.
124. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20: 657-664.
125. Sallam A, Taylor SR, Khan A et al. Factors determining visual outcome in endogenous candida endophthalmitis. Retina (Philadelphia, Pa.) 2012; 36(6): 1129-1134.
126. Riddell JT, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52: 648-653.
127. Grueb M, Rohrbach JM, Zierhut M. Amphotericin b in the therapy of Candida glabrata endophthalmitis after penetrating keratoplasty. Cornea 2006; 25: 1243-1244.
128. Gao H, Pennesi ME, Shah K et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004; 122: 1687-1692.
129. Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007; 51: 239-244.
130. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-140.
131. Casado JL, Quereda C, Oliva J et al. Candidal meningitis in hiv-infected patients: analysis of 14 cases. Clin Infect Dis 1997; 25: 673-676.
132. Houmeau L, Monfort-Gouraud M, Boccara JF, Badoual J. [candida meningitis, in a premature infant, treated with liposomal amphotericin b and flucytosine]. Arch Fr Pediatr 1993; 50: 227-230.
133. Jarlov JO, Born P, Bruun B. Candida albicans meningitis in a 27weeks premature infant treated with liposomal amphotericin-b (ambisome). Scand J Infect Dis 1995; 27: 419-420.
134. Chen TL, Chen HP, Fung CP, Lin MY, Yu KW, Liu CY. Clinical characteristics, treatment and prognostic factors of candidal meningitis in a teaching hospital in Taiwan. Scand J Infect Dis 2004; 36: 124-130.
135. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin b and 5-fluorocytosine for candida meningitis. Rev Infect Dis 1984; 6: 791-801.
136. Aleixo MJ, Caldeira L, Ferreira ML. Candida albicans meningitis: clinical case. J Infect 2000; 40: 191-192.
137. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
138. Weiler S, Fiegl D, MacFarland R et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55: 925-928.
139. Liu KH, Wu CJ, Chou CH et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol 2004; 42: 5950-5953.
140. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32: 50-62.
141. Lefort A, Chartier L, Podglajen I et al. French national prospective study of candida endocarditis (mycendo). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2010; M-1249.
142. Boland JM, Chung HH, Robberts FJ et al. Fungal prosthetic valve endocarditis: mayo clinic experience with a clinicopathological analysis. Mycoses 2011; 54: 354-360.
143. Falcone M, Barzaghi N, Carosi G et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine 2009; 88: 160-168.
144. Baddley JW, Benjamin DK Jr, Patel M et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27: 519-529.
145. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of candida endocarditis: a meta-analysis. Medicine 2011; 90: 237-249.
146. Aslam S, Hernandez M, Thornby J, Zeluff B, Darouiche RO. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50: 664-671.
147. Miller DJ, Mejicano GC. Vertebral osteomyelitis due to candida species: case report and literature review. Clin Infect Dis 2001; 33: 523-530.
148. Sugar AM, Saunders C, Diamond RD. Successful treatment of candida osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn Microbiol Infect Dis 1990; 13: 517-520.
149. Hennequin C, Bouree P, Hiesse C, Dupont B, Charpentier B. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis 1996; 23: 176-178.
150. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol 2008; 46: 79-83.
151. Horn D, Sae-Tia S, Neofytos D. Aspergillus osteomyelitis: review of 12 cases identified by the prospective antifungal therapy alliance registry. Diagn Microbiol Infect Dis 2009; 63: 384-387.
152. Legout L, Assal M, Rohner P, Lew D, Bernard L, Hoffmeyer P. Successful treatment of candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 2006; 38: 728-730.
153. Sim JP, Kho BC, Liu HS, Yung R, Chan JC. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J 2005; 11: 120-123.
154. Hansen BL, Andersen K. Fungal arthritis. A review. Scand J Rheumatol 1995; 24: 248-250.
155. Perez-Gomez A, Prieto A, Torresano M et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998; 27: 226-244.
156. Sili U, Yilmaz M, Ferhanoglu B, Mert A. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. Clin Infect Dis 2007; 45: 897-898.
157. Tunkel AR, Thomas CY, Wispelwey B. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. Am J Med 1993; 94: 100-103.
158. Levine M, Rehm SJ, Wilde AH. Infection with Candida albicans of a total knee arthroplasty. Case report and review of the literature. Clin Orthop Relat Res 1988; 226: 235-239.
159. Merrer J, Dupont B, Nieszkowska A, De Jonghe B, Outin H. Candida albicans prosthetic arthritis treated with fluconazole alone. J Infect 2001; 42: 208-209.
160. Cushing RD, Fulgenzi WR. Synovial fluid levels of fluconazole in a patient with Candida parapsilosis prosthetic joint infection who had an excellent clinical response. J Arthroplasty 1997; 12: 950.
161. Kelesidis T, Tsiodras S. Candida albicans prosthetic hip infection in elderly patients: is fluconazole monotherapy an option?Scand J Infect Dis 2010; 42: 12-21.
162. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12years in adult patients at a tertiary care hospital. Medicine 2002; 81: 425-433.
163. Garey KW, Neuhauser MM, Bearden DT et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006; 49: 226-231.
164. Anthony NG, Breen D, Clarke J et al. Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. J Med Chem 2007; 50: 6116-6125.
165. Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin b in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101: 170-176.
166. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin b alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-1413.
167. Payne JF, Keenum DG, Sternberg P Jr, Thliveris A, Kala A, Olsen TW. Concentrated intravitreal amphotericin b in fungal endophthalmitis. Arch Ophthalmol 2010; 128: 1546-1550.
168. Souri EN, Green WR. Intravitreal amphotericin b toxicity. Am J Ophthalmol 1974; 78: 77-81.
169. Cruciani M, Di Perri G, Molesini M, Vento S, Concia E, Bassetti D. Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis 1992; 11: 957.
170. van Hal SJ, Stark D, Harkness J, Marriott D. Candida dubliniensis meningitis as delayed sequela of treated c. Dubliniensis fungemia. Emerg Infect Dis 2008; 14: 327-329.
171. Lefort A, Chartier L, Sendid B et al. Diagnosis, management and outcome of candida endocarditis. Clin Microbiol Infect 2012; 18: E99-E109.
172. Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID Diagnostic and Management Guideline for Candida Diseases 2012: Developing European Guidelines in Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2012; 18(Suppl 7): 1-8.
173. Cuenca-Estrella M, Verweij P, Arendrup MC et al. ESCMID Diagnostic and Management Guidelines of Candida Diseases 2012: Diagnostic Procedures. Clin Microbiol Infect 2012; 18(Suppl 7): 9-18.